📰 Bio Newsroom
The latest trends and key papers in biomedical research, curated for you.
🔥 Latest
Cardiac toxicity revealed after gene therapy, with microdystrophin expression remaining below 1%
The number of elderly patients is rapidly increasing, but there is a lack of evidence to support treatment; it is urgent to design clinical trials that reflect the actual condition of elderly patients.
Successful Rescue of Organoid Differentiation and Reprogramming of Failed Stem Cells by Reversing Chromatin Status
Parental Age and Assisted Reproductive Technology Shape the Genomic Landscape of De Novo Mutations in Offspring
A 20,000-Year Analysis of Ancient Genomes Reveals the History of Genetic Isolation and Restoration Strategies for North American Bison
🗞️ News Wire
Cardiac toxicity revealed after gene therapy, with microdystrophin expression remaining below 1%
Background Duchenne Muscular Dystrophy (DMD) is caused by a genetic defect in the dystrophin protein gene, which is essential for maintaining muscle integrity. The progressive destruction of muscle cell membranes leads to a debilitating genetic disorder characterized by weakening of muscles throughout the body. Patients typically begin experiencing gait disturbances at a young age, eventually succumbing to respiratory and cardiac muscle failure. Cardiac muscle dysfunction, in particular, has been identified as a critical factor determining patient survival. Due to the lack of definitive treatments, management has been limited to supportive care aimed at alleviating symptoms. Recent advances in gene therapy have emerged as a promising alternative, focusing on compensating for damaged genes. This approach involves delivering a microdystrophin gene, which contains only the key functional regions of the dystrophin gene, into cells using an adeno-associated virus (AAV) vector. Delandistrogene Moxeparvovec (Elevidys), a representative drug, has generated significant expectations for its potential to restore muscle function in patients. However, the specific effects of gene therapy on cardiac tissue and clinical data on in vivo protein expression efficiency remain limited. Key Findings A research team led by Dr. Benjamin J. Samelson-Jones at the Children’s Hospital of Philadelphia (CHOP) meticulously tracked cardiac adverse events in a patient who received Elevidys, and the results have garnered attention. The study revealed that the patient exhibited signs of rapid cardiac function deterioration approximately 42 days after gene therapy administration. The medical team promptly initiated high-dose intravenous steroid treatment to mitigate myocardial damage. Furthermore, they implemented more intensive cardiac monitoring than the product label's recommended guidelines. To elucidate the biological mechanisms underlying the adverse effects observed after treatment, the research team collected cardiac and biceps muscle tissues from the patient for molecular biological analysis. The analysis confirmed that the expression levels of microdystrophin, the target protein, in both cardiac and skeletal muscle tissues were less than 1% of normal dystrophin levels. This indicates that the therapeutic gene was not adequately delivered into target cells or was not efficiently translated into protein. Furthermore, the limited amount of protein expressed exhibited a heterogeneous distribution, with patchy clusters rather than uniform distribution throughout the muscle cells. The fact that significant cardiac toxicity occurred despite such minimal gene delivery efficiency represents an unusual phenomenon that challenges conventional clinical understanding. Significance and Prospects Although this is a case report involving a single patient, it transparently demonstrates the uncertainties regarding the safety and efficacy of high-cost gene therapies. The observation that the heart was damaged despite inadequate microdystrophin production suggests that the immune response or cellular toxicity induced by the viral vector itself may have been a contributing factor. This highlights the potential for adverse effects to outweigh the therapeutic benefits. In the future, clinicians performing gene therapy should implement more detailed cardiac function monitoring protocols that go beyond the standard guidelines outlined in the existing product labels. Heterogeneous and sparse protein expression can disrupt the cardiac conduction system, posing a risk of potentially fatal arrhythmias. The biotechnology industry also faces significant challenges. Research is needed to develop next-generation vector designs that enhance AAV delivery efficiency while minimizing immunogenicity, and to optimize the dosage regimen.
The number of elderly patients is rapidly increasing, but there is a lack of evidence to support treatment; it is urgent to design clinical trials that reflect the actual condition of elderly patients.
Background With the development of medical technology and changes in population structure, elderly patients have become the fastest-growing group in modern medical practice. However, the scientific evidence to determine their treatment methods is significantly lacking. Existing clinical trials for new drug development have primarily focused on demonstrating the efficacy of drugs by including young patients with no comorbidities or good physical function. This selection method does not reflect the health status of elderly patients who often have multiple diseases and take multiple medications simultaneously. As a result, when the drug efficacy derived from clinical trials is applied to elderly patients in actual clinical practice, unexpected side effects or reduced efficacy may occur. Key Findings An international research team led by Professor Hans Wildiers of the University of Leuven in Belgium presented specific improvements in the design of clinical trials for elderly patients in a review article published in the medical journal The Lancet. The researchers identified three key areas to improve the usefulness of clinical trials, considering the high heterogeneity of elderly patient populations. The first area is to lower the threshold for recruiting participants to better represent the actual patient population. By relaxing the strict exclusion criteria, patients with comorbidities or slightly impaired physical function should be allowed to participate in clinical trials to obtain data that is more consistent with actual clinical practice. The second area aims to optimize therapeutic interventions by considering the physiological characteristics of elderly patients. This includes adjusting treatment doses to reflect polypharmacy or geriatric syndromes such as frailty, or incorporating de-escalation or non-treatment strategies into the clinical trial design instead of aggressive drug therapy. The third area involves establishing new evaluation indicators to measure clinically meaningful outcomes in elderly patients. Instead of focusing solely on indicators such as overall survival (OS) or progression-free survival (PFS), the study suggests that quality of life (QOL), maintenance of physical function, and the ability to live independently should be considered as major evaluation factors to assess the actual therapeutic value. The researchers pointed out that, although there have been increasing calls for these improvements over the past 10 years, the actual changes in research practice have been slow. Recently, however, there have been encouraging examples of successful trials that have been designed to better reflect actual clinical situations, thereby encouraging the participation of elderly patients and obtaining meaningful comparative data. In addition, the researchers added that combining clinical trial results with observational studies using real-world data (RWD) can provide a valuable complementary source of evidence to supplement the limitations of clinical trials. Significance and Prospects This study is expected to provide guidelines to the pharmaceutical and biotechnology industries and regulatory agencies for verifying treatments tailored to elderly patients. As regulatory agencies increasingly scrutinize the inclusion of data from elderly patients in new drug approval reviews, they are also demanding stricter representation of the clinical trial population. As a result, global pharmaceutical companies have begun to incorporate the comorbidities and physical frailty of elderly patients into the design of clinical trials from the initial stages. However, there are still many challenges to be addressed before these changes can be fully implemented. Relaxing the criteria for clinical trial participation may increase the risk of unexpected side effects and failure to demonstrate the efficacy of the drug, and it will also increase the cost and complexity of clinical operations. Ultimately, the key challenge is to find an appropriate balance between the precision of clinical trials and the representativeness of real-world clinical settings. If elderly patients are at the center of decision-making through this process, the industry expects that it will pave the way for reducing unnecessary overtreatment and providing the most appropriate medical services for individual needs.
Successful Rescue of Organoid Differentiation and Reprogramming of Failed Stem Cells by Reversing Chromatin Status
Background Human pluripotent stem cells (hPSCs) possess the potential to differentiate into all cell types in the human body. In particular, patient-specific induced pluripotent stem cells (hiPSCs) are considered key materials for creating organoids, such as brain and kidney organoids. However, in actual research settings, the differentiation efficiency varies significantly between cell lines, which has often posed a problem that reduces the reliability of research results. Even under the same conditions, some hPSC cell lines differentiate well into brain organoids, while others differentiate into other tissues instead of the brain or stop developing. To elucidate the cause, the academic community has tracked genetic factors such as DNA sequence changes and DNA methylation, but these alone could not fully explain the differentiation differences. It has been revealed that specific cell lines lose their differentiation ability due to epigenetic modifications that occur naturally during the culture process. In particular, the phenomenon in which the pathway leading to nerve cells is blocked has been identified as a critical weakness in disease modeling and therapeutic development. There was a need for a technology that could erase the unique memory of stem cells and restore their differentiation ability. Key Findings The research team led by Dr. Madeline Lancaster at the University of Cambridge, UK, has discovered that the limit of stem cell differentiation ability is determined at the chromatin level. The research team found that cell lines that fail to form brain organoids are fixed in a posterior epiblast-like state, which forms the posterior tissue during embryonic development. These cells tend to express genes that form the spinal cord or tail early, before differentiating into the anterior tissue, the brain. The researchers confirmed that this abnormal state results from the loss of bivalent chromatin, which regulates gene expression. The research team devised a chemical chromatin restoration (CHR) protocol to normalize chromatin. This three-step technique works by blocking H3K9 methylase, a chromatin repressor marker, and adjusting the concentration of cell growth factors. As a result of applying this treatment, hiPSCs successfully recovered their original undifferentiated state, the competent anterior epiblast-like state. These cell lines began to form cortical organoids. Specific experimental data also confirms this. When the expression rate of the SOX2 marker, an indicator of brain organoid development, was measured, the abnormal cell line sojd3 showed a sharp increase from the previous 4.44% to 60.72% after CHR. The burb1 cell line also increased from 2.75% to 66.71%. The expression rate of PAX8, a kidney organoid development marker, increased from 0.74% to 42.68% for sojd3, and the organoid marker CDX2 also increased significantly from 0.41% to 14.21%. Significance and Prospects This discovery shows that the fate of stem cells is not fixed but is a flexible system that can be reset by chemical manipulation. In particular, the fact that the differentiation potential of cells was restored by regulating only histone modifications without touching DNA methylation is considered positive in terms of safety. The CHR technique proposed by the researchers can be performed by treating only with small molecule compounds without gene editing, which has very high industrial application value. This opens the way to bring many patient-derived stem cell lines, which have been put on hold due to differentiation bias, back into the research field. However, there are still many challenges to be solved before this technology can be directly introduced into a standard cell therapy production process. It is necessary to thoroughly verify whether long-term genomic stability is maintained when the CHR protocol is consistently applied to various stem cell lines. Subsequent research should follow to refine the culture medium composition so that bivalent chromatin does not erode again in large-scale culture environments. It is also an important research task to establish criteria for epigenetic fine-tuning to increase the maturity of organoids to an adult level.
Parental Age and Assisted Reproductive Technology Shape the Genomic Landscape of De Novo Mutations in Offspring
Background De novo mutations (DNMs), which are newly arising mutations in offspring that are not present in their parents, are a source of human genetic diversity and also contribute to the etiology of some rare diseases and developmental disorders. Given that sperm precursor cells undergo continuous division throughout a male's lifetime, paternal age is a known major factor increasing the number of DNMs in offspring. Maternal age has also been suggested to be associated with DNMs, potentially due to oocyte aging, chromosomal segregation errors, and specific types of point mutations. Assisted reproductive technology (ART), including in vitro fertilization and intracytoplasmic sperm injection, is increasingly utilized. However, it is unclear whether the processes involved in ART, such as gamete handling, embryo culture, and fertilization methods, introduce new mutations into the offspring's genome. ART users tend to have a higher average age at conception and may have underlying biological factors related to infertility, making it difficult to distinguish the effects of the procedure from those of parental age and baseline reproductive capacity. Previous studies have been limited by small sample sizes or a focus on specific chromosomal abnormalities and epigenetic changes, hindering a comprehensive assessment of the spectrum of rare DNMs. Key Findings The researchers analyzed whole-genome sequencing (WGS) data from 7,851 parent-offspring families. They identified variants present in the offspring but not in the parents and conducted a large-scale, family-based study to analyze the association between parental age, ART use, and the number and types of DNMs. Unlike exome sequencing, which only analyzes a portion of the genome, WGS captures variants across the entire genome, including non-coding regions. The analysis revealed that parental age was associated with the overall burden of DNMs in offspring, and the effect of age extended beyond simply the number of variants. Differences were also observed in the types of variants that occurred. ART was also identified as a factor that leaves a distinct trace on the number and spectrum of DNMs. This provides clues to track the biological processes in which mutations arise, going beyond the approach of simply comparing the average number of variants in naturally conceived and ART-conceived offspring. However, the published abstract does not provide the number of additional variants per year of parental age, the effect size and confidence interval for specific ART procedures. The abstract also does not provide sufficient evidence to conclude that a specific procedure directly causes a specific mutation. The study results should be interpreted as demonstrating an association between parental age and ART and the patterns of genetic variation in offspring. Significance and Implications The strength of this study lies in its large sample size of 7,851 families and the combination of parental and offspring WGS data. Rare DNMs may not show statistically significant signals in small cohorts, but analyzing thousands of families allows for a more robust identification of subtle differences in mutation spectra associated with parental age and reproductive procedures. In the future, this may serve as a basis for estimating risk by mutation type in genetic counseling, going beyond simply explaining average age-related risks. However, this does not imply an immediate warning about the safety of ART. Even if the number or proportion of DNMs increases, most of them do not affect health, and the actual risk of disease varies greatly depending on the location and function of the mutation and its presence in the embryo. Other confounding factors, such as the cause of infertility, parental lifestyle, whether gametes are donated, and culture conditions, also need to be considered. The next steps are replication studies of specific ART procedures and long-term clinical follow-up. If an increase in mutations is confirmed in a specific process, there is room to reduce the risk by adjusting the culture period, temperature, oxidative stress, and gamete handling methods. It is also necessary to verify whether the same signals are observed in different populations and medical institutions, and whether the observed mutations are associated with the actual incidence of childhood diseases, before they can be reflected in clinical guidelines.
A 20,000-Year Analysis of Ancient Genomes Reveals the History of Genetic Isolation and Restoration Strategies for North American Bison
Background North American bison (Bison bison), a symbol of the United States, once roamed the plains in herds of tens of millions. Due to indiscriminate hunting and development, their population plummeted to just a few hundred individuals by the late 19th century, creating a bottleneck. Conservation efforts in the 20th century, aimed at preventing extinction, inadvertently created new challenges. The surviving bison herds were confined to small, isolated reserves and managed on a limited scale. Concerns arose about the potential contamination of the species' genetic purity due to the introduction of genes from domesticated cattle. To fully restore bison to their ecosystem, it is necessary to establish clear criteria for understanding their past genetic history and the genetic health of modern herds. Previous analyses focused only on surviving modern populations, limiting the ability to elucidate the original genetic makeup. Key Findings An international research team attempted to address this challenge by conducting large-scale genomic sequencing. They integrated genomic information from 115 ancient bison remains collected from sites in Wyoming and 45 modern bison. This was combined with 52 existing datasets, resulting in a comprehensive genetic dataset of 212 individuals. The analysis revealed findings that challenged conventional wisdom. Until the population decline in the late 19th century, North American bison were connected in a vast genetic network across the continent. Genetic differences between regions were minimal. The isolation and divergence observed in modern herds are not natural phenomena but rather the result of genetic drift that occurred in small, isolated populations within conservation reserves after the 20th century. The study also investigated the long-standing debate in conservation regarding the introgression of cattle genes. There were concerns that the DNA of domesticated cattle had permanently mixed into the genomes of modern bison due to past artificial breeding. However, the actual analysis revealed that the traces of cattle genes were less significant than expected. Among the 97 modern plains bison studied, only 32 individuals showed evidence of cattle genes. Furthermore, the introduced DNA fragments were confined to a very small region of the genome, suggesting that they can be eliminated through selective breeding and genetic management over generations. The genetic relationship between the plains bison and wood bison subspecies was also established. Forced translocation efforts in the 1920s, aimed at increasing population numbers, disrupted the boundaries between the two subspecies. It was confirmed that all existing wood bison populations inherited genetic material from the plains bison. Significance and Prospects This research demonstrates that ancient genomics provides a practical roadmap for conservation genomics in endangered species. It opens the door to actively utilizing modern bison herds, which were previously excluded due to the presence of cattle genes. A refined management model is possible, allowing for the preservation of genetic diversity while reducing the presence of cattle genes. However, the geographic environment of North America is different from the past, when bison freely roamed the continent. Due to fragmented habitats, restoring the natural connectivity of wild populations is nearly impossible. A sophisticated conservation strategy is needed, involving human-mediated transfer of individuals between isolated small populations. The research team hopes that the genomic map will serve as a blueprint for creating ecological corridors where humans and wildlife can coexist.
Myostatin Loss-of-Function Variants Increase Muscle Mass and Decrease Body Fat
Background Myostatin is a protein produced by the MSTN gene that stimulates ActRII signaling, thereby inhibiting the growth and differentiation of skeletal muscle. In mice, deletion of MSTN more than doubles muscle mass, but in humans, evidence has been limited to a few cases of congenital muscle hypertrophy. Myostatin-blocking antibodies in adults have only increased muscle mass by 2-4%, a significant difference from animal studies. Recently, the glucagon-like peptide-1 receptor (GLP-1R) agonists have brought this pathway back into focus. Up to one-third of the weight loss achieved with GLP-1R drugs may be due to skeletal muscle loss. In particular, older adults with poor muscle recovery may be at increased risk of sarcopenia after obesity treatment. However, evaluating the human effects and long-term safety of rare MSTN variants requires a much larger sample size than previous studies. Key Findings The researchers analyzed exomes from 11 cohorts, totaling 1.1 million individuals. Among the 13,454 individuals carrying 506 rare MSTN variants (allele frequency <0.5%), 38 were predicted to be loss-of-function variants, and 188 were classified as impairing protein function. Individuals with loss-of-function variants did not differ in overall weight, but had lower body fat percentage and higher lean mass, as measured by bioelectrical impedance analysis. The statistical significance was P=2.2×10⁻⁷ for body fat percentage and P=1.5×10⁻⁷ for grip strength. Whole-body Dixon MRI scans from 77,572 participants in the UK Biobank were analyzed using two types of deep learning segmentation models. The results showed that individuals with variants had increased muscle water volume in several muscle groups and decreased fat tissue volume and intramuscular fat infiltration. Individuals heterozygous for variants close to loss-of-function had 5-8% more total muscle mass, and some muscle groups, such as the gluteus maximus, had more than 10% more. Arg65His, Thr115Met, Ile225Thr, and Arg283Cys were the four variants that drove the muscle-increasing signal. The effect of the relatively common Ile225Thr variant was about 20% of that of Arg283Cys, supporting a dose-response relationship between the degree of MSTN inhibition and muscle mass. One individual heterozygous for Arg65His had 31.8% lower body fat percentage and 12.3% higher lean mass than expected, but this is only a single case and not sufficient to confirm the effect size. Significance and Outlook These results provide large-scale genetic evidence that partial myostatin inhibition throughout life can increase muscle mass and strength while reducing fat mass in humans. Cardiac MRI showed no signs of ventricular wall hypertrophy, and there was no strong association with heart failure, hypertrophic cardiomyopathy, or reproductive markers. This indirectly supports the long-term safety of drug inhibition, but lifelong exposure in individuals with genetic variants cannot be equated with drug administration in adulthood. There was a trend toward protection in waist-to-hip ratio and glycated hemoglobin, but statistical evidence was not sufficient to confirm a reduction in the risk of diabetes or cardiovascular disease. The frequency of the three variants was also very low, less than 0.01%. The protein stabilization and aggregation mechanisms proposed by the researchers using AlphaFold2 also need to be confirmed by cell and biochemical experiments. This study is more of a human genetic map for determining the appropriate degree of myostatin inhibition and evaluation parameters for myostatin inhibitors, rather than a clinical trial that proves efficacy. Original article
Calcium phosphate nanoparticles successfully target and inhibit TRIB3 protein, overcoming a hurdle in lung cancer treatment
Background Non-small cell lung cancer (NSCLC) is a common and aggressive malignancy, accounting for approximately 85% of all lung cancer patients. While targeted therapies against specific gene mutations are continuously being developed, many patients still face challenges due to drug resistance and metastasis. In particular, the protein tribbles pseudokinase 3 (TRIB3), which disrupts intracellular signaling and promotes the survival and metastasis of cancer cells, is known as a key factor that worsens prognosis. Clinical data support this, showing that patients with high levels of TRIB3 have relatively lower survival rates. However, the development of targeted therapies that directly inhibit the TRIB3 protein has been hampered by technical limitations. This is because the protein structure makes it difficult to block the binding site with conventional compound-based drugs. Small interfering RNA (siRNA) technology, which inhibits gene expression itself, has emerged as an alternative, but it also faces the challenge of being easily degraded in the blood and difficult to penetrate cell membranes. To overcome these delivery limitations, calcium phosphate (CaP) nanoparticles, which are highly biocompatible and stable in serum, are emerging as a new alternative. Key Findings The research team, led by Professor Yinqiu Wu at Yangzhou University, developed calcium phosphate nanoparticles (NP RESULTS: In KP-1 cell experiments, NP CONCLUSION: This study is significant because it successfully blocks the TRIB3 protein, which has been extremely difficult to develop drugs for, using a safe, biocompatible mineral-based delivery system. In particular, by using a non-toxic calcium phosphate material, it effectively bypasses the problem of toxicity of the delivery system itself, which has been a major hurdle in gene therapy. This is expected to be a catalyst for the active introduction of gene silencing technology in NSCLC treatment in the future. However, there are also clear challenges to be addressed before it can be applied to actual patients. It is unclear whether the excellent results confirmed in the preclinical stage will be reproduced in the complex immune system and tumor microenvironment of humans. In addition, it is necessary to minimize the off-target effects, which are slightly delivered to tissues other than the target tumor during intravenous administration. Furthermore, it is essential to standardize the process to maintain a uniform size of the nanoparticles during large-scale production.
Development of a dengue mRNA vaccine candidate targeting all four serotypes simultaneously through consensus antigen design
Background Dengue fever is a major mosquito-borne infectious disease that poses a significant global health problem. Dengue virus (DENV) exists in four distinct serotypes (DENV-1 to 4). A medical challenge arises when a patient infected with a specific serotype is exposed to another serotype, which can lead to a rapid worsening of symptoms. This phenomenon, known as antibody-dependent enhancement (ADE), has been a long-standing obstacle in vaccine development. A vaccine design that can equally block all four viruses is required. The scientific community has identified non-structural protein 1 (NS1), which is released from DENV-infected cells, as a new alternative. This protein promotes vascular leakage in patients, exacerbating symptoms, and also acts as an antigen that stimulates immune cells. Research continues to develop vaccines that incorporate NS1 to prevent severe dengue fever. However, overcoming the genetic variations between serotypes and inducing uniform immunity is not easy. Key Findings The researchers performed integrated sequence analysis of the four DENV serotypes to design a single consensus antigen (cNS1). This consensus antigen exhibits 78-89% amino acid sequence similarity to the NS1 proteins of the four serotypes found in nature. The researchers created a vaccine formulation (mRNA-LNP) by incorporating the designed cNS1 sequence into a modified messenger RNA (mRNA) and encapsulating it in lipid nanoparticles (LNP). Animal experiments were conducted to directly verify the efficacy of the vaccine. When a low dose (0.2 µg) of the cNS1 vaccine was administered to BALB/c mice, a broad immunoglobulin G (IgG) antibody response was observed, recognizing the NS1 protein of all four serotypes. In addition to humoral immunity, cellular immune responses were also induced. This was confirmed by the presence of T cell immune responses that produce interferon-gamma (IFN-γ) in response to peptides derived from multiple DENV serotypes. However, some trade-offs were revealed in the process of achieving a broad immune response. While the ability to recognize all four serotypes was achieved, the production of serotype-specific antibodies was somewhat reduced compared to when only a single serotype was targeted. This is a common challenge encountered when developing multivalent vaccines. Significance and Prospects This study demonstrates the potential of a single antigen design to simultaneously inhibit multiple variants of DENV. Existing dengue vaccines mainly target envelope proteins. This approach carries the risk of adverse effects due to incomplete antibody formation, which can worsen infection. In contrast, targeting the NS1 protein released from infected cells can easily avoid these concerns. Ultimately, the cNS1 antigen designed in this study is expected to be used as an adjuvant component of next-generation dengue vaccines. When administered together with an envelope protein-based vaccine, it can simultaneously activate antibody responses and cellular immunity, enhancing protective efficacy. Due to the characteristics of mRNA technology, which allows for rapid adjustment of gene sequences, it also has advantages in establishing a large-scale production system. However, several obstacles must be overcome before the vaccine can be commercialized. This study is in the basic research stage and uses only a mouse model. A challenge experiment is also essential to verify whether the vaccinated animals can defend against actual viral infection. Furthermore, further research on formulations is needed to compensate for the relatively low induction of antibodies targeting specific serotypes.
Enhanced mRNA Therapeutic Delivery with Redox-Responsive Smart Nanocarriers
Background Messenger RNA (mRNA)-based therapeutics have expanded beyond their success in COVID-19 vaccines to include cancer immunotherapy, gene editing, and protein replacement therapy for rare diseases. To ensure that injected mRNA remains intact and reaches target cells, a delivery system is essential for safe and effective transport. Lipid nanoparticles (LNPs), widely used in clinical settings, have demonstrated their utility but still require improvement. Key limitations include lower-than-expected intracellular delivery efficiency and potential immunogenicity due to accumulation in the body after repeated administration. Conventional LNPs tend to be trapped in endosomes after crossing the cell membrane, leading to mRNA degradation if they cannot escape. To efficiently release therapeutic genetic material into the cytoplasm, the development of intelligent materials that change their structure in response to specific microenvironments is crucial. This has led researchers to focus on developing smart nanocarriers that can precisely release drugs by recognizing physiological characteristics of disease sites or cells. Key Findings The researchers comprehensively analyzed various nanocarrier technologies that utilize redox (oxidation-reduction) responsiveness, considering the chemical environment both inside and outside cells. Compared to normal cells, the intracellular and tumor microenvironments exhibit significantly higher glutathione (GSH) concentrations (hundreds of times higher) and increased production of reactive oxygen species (ROS). Nanomaterials designed to release drugs in response to these concentration differences are the core of redox-responsive nanocarriers. The main technology platforms are classified into reduction-responsive, oxidation-responsive, and dual-responsive systems. Reduction-responsive carriers incorporate disulfide bonds into their molecular structure, allowing them to break down and rapidly release mRNA when exposed to high GSH concentrations within cells. Oxidation-responsive platforms utilize the characteristic of certain hydrophobic materials changing to hydrophilic in the excessive ROS environment of tumors or inflammatory sites, inducing the breakdown of the carrier. Recently, hybrid nanocarriers combining the advantages of polymers and lipids have been synthesized, successfully enhancing both stability and cell permeability. These carriers are precisely controlled to maintain their integrity during circulation in the body and disassemble upon entering cells. Significance and Outlook Redox-responsive smart nanocarriers have the potential to significantly improve the targeted delivery efficiency of mRNA therapeutics. By greatly improving the efficiency of endosomal escape, which is the process by which therapeutic molecules reach the cytoplasm, they can enhance therapeutic effects and reduce the required dosage. This, in turn, can mitigate systemic side effects associated with drug overdoses. However, there are clear challenges to be addressed before commercialization. The long-term safety of nanomaterials in terms of their degradation and excretion in the body must be definitively demonstrated. The technology also needs further research to control potential immunogenicity that may arise during repeated administration. Furthermore, the standardization of manufacturing processes for the large-scale production of uniform-quality nanoparticles is a critical industrial hurdle. In the future, researchers plan to introduce artificial intelligence (AI) to predict optimal responsive chemical structures and expand the scope of application to personalized theranostic systems that combine diagnosis and treatment.
Identification of CDHR1 variants that disrupt retinal structure and the potential for gene therapy
Background Retinal degeneration, a leading cause of vision loss, significantly impacts patients' quality of life. Recent research has identified the CDHR1 gene as a major cause of autosomal recessive retinal degeneration, garnering considerable attention. Mutations in this gene manifest as three distinct phenotypes: macular dystrophy, cone-rod dystrophy, and retinitis pigmentosa. Macular dystrophy, in particular, closely resembles age-related macular degeneration (AMD) in terms of morphology, leading to frequent misdiagnoses in clinical settings. This is largely due to the presence of silent nucleotide substitutions, which are difficult to detect with conventional genetic testing. Consequently, patients have been denied appropriate treatment opportunities for an extended period. Key Findings CDHR1 is a non-classical cadherin protein expressed in photoreceptor cells, including cones and rods, which receive visual information. This protein plays a crucial role in maintaining the alignment of the outer segment, a critical structure for light detection. Researchers utilized a CDHR1 knockout mouse model (Cdhr1 Knockout Mouse) to evaluate the potential of adeno-associated virus (AAV) gene supplementation therapy. Mice treated with the therapeutic agent via subretinal injection exhibited long-term improvements in retinal structure and visual behavioral function. This was attributed to the restoration of the original length of the shortened and disorganized photoreceptor outer segments and increased cell survival in the disease model. The researchers demonstrated that patients with silent nucleotide substitutions and hypomorphic variants, which retain some gene function, may also benefit from the treatment. Furthermore, the study presents a clinically applicable diagnostic flowchart, which is noteworthy. The flowchart establishes criteria for accurately distinguishing CDHR1 variants from similar ABCA4, PRPH2, and GUCY2D gene mutations associated with macular dystrophy. Significance and Prospects This research is recognized for overcoming the limitations of gene therapy delivery and expanding the possibilities of personalized medicine. The CDHR1 gene's entire coding sequence is of a size that can be readily inserted into a standard AAV vector, making therapeutic development relatively straightforward. This genetic characteristic is likely to be a positive factor in accelerating the drug approval process in the future. The possibility that some patients previously diagnosed with dry AMD may actually have CDHR1 variants necessitates a comprehensive re-evaluation of existing genetic diagnostic systems. Adding silent nucleotide substitutions to the diagnostic gene panel is essential to ensure that patients receive appropriate treatment. However, there are challenges to overcome before the results obtained in animal models can be applied to humans. Subsequent research is needed to address concerns about ocular damage associated with subretinal injection and to demonstrate the long-term safety of the therapeutic gene.